Skip to main content
. 2018 May 29;9(41):26527–26542. doi: 10.18632/oncotarget.25480

Figure 2. Tz, RA and the combination of both drugs decrease SKBR3 and BT-474 cell viability.

Figure 2

MTT assay at different doses. (A) SKBR3 cells and (B) BT-474 cells were treated with increasing doses of Tz (0.1-1-10-100 μg/ml), RA (10-8-10-7-10-6-10-5-10-4 M) or the combination of Tz (1-10-100 μg/ml) with 10-6M RA for 72 h. The results express the percentage (%) of surviving cells compared to the control (Con, 100% survival). All data shown are representative of three independent experiments. Error bars indicate standard deviations. *P <0.05 vs. Control.